Glomerulonephritis (Genitourinary Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis – Drugs In Development, 2021, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 19, 11, 2, 29, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).

– The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Alexion Pharmaceuticals Inc

Algomedix Inc

Alnylam Pharmaceuticals Inc

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp

Apellis Pharmaceuticals Inc

Biogen Inc

Bird Rock Bio Inc

Bristol Myers Squibb Co

Cabaletta Bio Inc

Calliditas Therapeutics AB

Cellmid Ltd

Certa Therapeutics Pty Ltd

ChemoCentryx Inc

Chinook Therapeutics Inc

Coegin Pharma AS

Complexa Inc

Cytodesign Inc

Delta 4 GmbH

DiaMedica Therapeutics Inc

Dimerix Ltd

Eledon Pharmaceuticals Inc

Ergon Pharmaceuticals LLC

Generian Pharmaceuticals Inc

Goldfinch Bio Inc

HanAll Biopharma Co Ltd

IGAN Biosciences Inc

Integral Molecular Inc

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

KeyMed Biosciences Inc

Kiniksa Pharmaceuticals Ltd

Kyowa Kirin Co Ltd

Mallinckrodt Plc

MorphoSys AG

Novartis AG

NovelMed Therapeutics Inc

Omeros Corp

Oraxion Therapeutics Inc

Pfizer Inc

Polaris Pharmaceuticals Inc

Polyneuron Pharmaceuticals AG

Puretech Health Plc

Ra Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Rohto Pharmaceutical Co Ltd

Rongchang Pharmaceuticals Ltd

Shanghai Alebund Pharmaceuticals Ltd

Slate Bio Inc

Sujana Biotech, LLC

Surrozen Inc

Takeda Pharmaceutical Co Ltd

Transcenta Holding Ltd

Travere Therapeutics Inc

Vera Therapeutics Inc

Vertex Pharmaceuticals Inc

Visterra Inc

Wuhan LL Science and Technology Development Co Ltd

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Glomerulonephritis - Overview

Glomerulonephritis - Therapeutics Development

Glomerulonephritis - Therapeutics Assessment

Glomerulonephritis - Companies Involved in Therapeutics Development

Glomerulonephritis - Drug Profiles

Glomerulonephritis - Dormant Projects

Glomerulonephritis - Discontinued Products

Glomerulonephritis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Glomerulonephritis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Glomerulonephritis – Pipeline by Alexion Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Algomedix Inc, 2021

Glomerulonephritis – Pipeline by Alnylam Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Amyndas Pharmaceuticals LLC, 2021

Glomerulonephritis – Pipeline by Angion Biomedica Corp, 2021

Glomerulonephritis – Pipeline by Apellis Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Biogen Inc, 2021

Glomerulonephritis – Pipeline by Bird Rock Bio Inc, 2021

Glomerulonephritis – Pipeline by Bristol Myers Squibb Co, 2021

Glomerulonephritis – Pipeline by Cabaletta Bio Inc, 2021

Glomerulonephritis – Pipeline by Calliditas Therapeutics AB, 2021

Glomerulonephritis – Pipeline by Cellmid Ltd, 2021

Glomerulonephritis – Pipeline by Certa Therapeutics Pty Ltd, 2021

Glomerulonephritis – Pipeline by ChemoCentryx Inc, 2021

Glomerulonephritis – Pipeline by Chinook Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Coegin Pharma AS, 2021

Glomerulonephritis – Pipeline by Complexa Inc, 2021

Glomerulonephritis – Pipeline by Cytodesign Inc, 2021

Glomerulonephritis – Pipeline by Delta 4 GmbH, 2021

Glomerulonephritis – Pipeline by DiaMedica Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Dimerix Ltd, 2021

Glomerulonephritis – Pipeline by Eledon Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Ergon Pharmaceuticals LLC, 2021

Glomerulonephritis – Pipeline by Generian Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Goldfinch Bio Inc, 2021

Glomerulonephritis – Pipeline by HanAll Biopharma Co Ltd, 2021

Glomerulonephritis – Pipeline by IGAN Biosciences Inc, 2021

Glomerulonephritis – Pipeline by Integral Molecular Inc, 2021

Glomerulonephritis – Pipeline by INVENT Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Ionis Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Glomerulonephritis – Pipeline by KeyMed Biosciences Inc, 2021

Glomerulonephritis – Pipeline by Kiniksa Pharmaceuticals Ltd, 2021

Glomerulonephritis – Pipeline by Kyowa Kirin Co Ltd, 2021

Glomerulonephritis – Pipeline by Mallinckrodt Plc, 2021

Glomerulonephritis – Pipeline by MorphoSys AG, 2021

Glomerulonephritis – Pipeline by Novartis AG, 2021

Glomerulonephritis – Pipeline by NovelMed Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Omeros Corp, 2021

Glomerulonephritis – Pipeline by Oraxion Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Pfizer Inc, 2021

Glomerulonephritis – Pipeline by Polaris Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Polyneuron Pharmaceuticals AG, 2021

Glomerulonephritis – Pipeline by Puretech Health Plc, 2021

Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Reata Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Rohto Pharmaceutical Co Ltd, 2021

Glomerulonephritis – Pipeline by Rongchang Pharmaceuticals Ltd, 2021

Glomerulonephritis – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2021

Glomerulonephritis – Pipeline by Slate Bio Inc, 2021

Glomerulonephritis – Pipeline by Sujana Biotech, LLC, 2021

Glomerulonephritis – Pipeline by Surrozen Inc, 2021

Glomerulonephritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Glomerulonephritis – Pipeline by Transcenta Holding Ltd, 2021

Glomerulonephritis – Pipeline by Travere Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Vera Therapeutics Inc, 2021

Glomerulonephritis – Pipeline by Vertex Pharmaceuticals Inc, 2021

Glomerulonephritis – Pipeline by Visterra Inc, 2021

Glomerulonephritis – Dormant Projects, 2021

Glomerulonephritis – Dormant Projects, 2021 (Contd..1)

Glomerulonephritis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Glomerulonephritis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports